

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- **Name:** Krisztian Homicsko
  - **Current Position & Affiliation:** Chef de Clinique, January, 2011-, Department of Oncology, Service of Immune Oncology (ION) University Hospital Centre of Vaud Canton, CHUV, Lausanne, Switzerland 75%
  - **Country:** Switzerland
- 

**Educational Background:**

- |           |   |
|-----------|---|
| 1995-2001 | Semmelweis University, Medical Diploma and Thesis, Summa cum laude  |
| 2001-2002 | University of Geneva, Specialisation in Medical Biology, DEA (M.Sc.)  |
| 2002-2006 | University of Lausanne, MD-PhD Thesis   |
| 2009-2013 | Medical Oncology Training Program, Department of Oncology, University Hospital Centre of Vaud Canton, CHUV, Lausanne, Switzerland |
| Nov 2010  | FMH/ESMO Examination in Clinical Oncology   |
| Dec 2010  | Oral examination of Specialisation in Medical Oncology of FMH   |
| 2010      | ECCO-AACR-ASCO Workshop "Methods in Clinical Cancer Research"   |
| 2011      | Training in "Molecular markers of cancer" by NCI-ASCO-EORTC, Brussels, Belgium  |
| 2012      | Swissmedic GCP certificate level 1,2,3: Bern, Switzerland   |
| 2018      | Certification GCP TRREE   |

**Professional Experience:**
**Currently:**

- Chef de Clinique, January, 2011-, Department of Oncology, Service of Immune Oncology (ION) University Hospital Centre of Vaud Canton, CHUV, Lausanne, Switzerland 75%
- Responsible of the Molecular tumor board of Department of Oncology Since January 2016, Joint appointment by the Centre for Personalized Oncology (CPO) and ION of CHUV
- Lab head, Department of Oncology since 2021

**Previous positions:**

- Resident in Oncology, Medical Oncology Training Program, Department of Oncology, University Hospital Centre of Vaud Canton, CHUV, Lausanne, Switzerland April 2009- December 2010
- Medical Fellow (Medecin Assistant), Curie Institute, Paris, France April 2008 – April 2009,
- Senior House Officer (SHO) Internal medicine at the Department of Intensive Care and Anaesthesiology, University of Semmelweis, Budapest, Hungary September 2007 March 2008
- Senior House Officer (SHO), University Hospital, Dundee, Scotland, UK January 2007- July 2007

**Main Scientific Publications:**
**Publications (10 publications), total number of papers 47, Hirsch index: 17**

1. .Sphingolipids Control Dermal Fibroblast Heterogeneity, Laura Capolupo, Irina Khven, Alex R. Lederer, Luigi Mazzeo, Galina Glousker, Sylvia Ho, Francesco Russo, Jonathan Paz Montoya,

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- Dhaka R. Bhandari, Andrew P. Bowman, Shane R. Ellis, Romain Guiet, Olivier Burri, Johanna Detzner, Johannes Muthing, Krisztian Homicsko, Francois Kuonen, Michel Gilliet, Bernhard Spengler, Ron M.A. Heeren, Gian Paolo Dotto, Gioele La Manno, and Giovanni D'Angelo, Science, Approved for publication 2022
2. Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed autologous tumoroids; Devanjali Dutta, François Rivest, L. Francisco Lorenzo Martín, Nicolas Broguiere, Simone Ragusa Nathalie Brandenburg, Sylke Höhnel, Damien Saugy, Sylvie Rusakiewicz, Krisztian Homicsko, George Coukos, Matthias Lutolf, bioRxiv, <https://doi.org/10.1101/2021.03.30.437679>
  3. Cancer cells retrace a stepwise differentiation program during malignant progression Sadegh Saghaforoush, Krisztian Homicsko, Annunziata Di Domenico, Stephan Wullschlegler, Aurel Perren, Ilaria Marinoni, Giovanni Ciriello, Iacovos P. Michael, and Douglas Hanahan (Cancer Discovery 2021 Apr 28; candisc.1637.2020. doi: 10.1158/2159-8290.CD-20-1637.)
  1. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays, Brandenburg N, Hoehnel S, Kuttler F, Homicsko K, Ceroni C, Ringel T, Gjorevski N, Schwank G, Coukos G, Turcatti G, Lutolf MP. Nat Biomed Eng 2020 Sep;4(9):863-874.
  2. Organoid technology and applications in cancer immunotherapy and precision medicine, Current Opinion in Biotechnology, Homicsko K., (2020)
  3. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klamann I, Danenberg E, Ioannidou K, Kandalafi L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE. Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311.
  4. Phase I trial of the oral smoothed inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK). Invest New Drugs. 2017 Dec;35(6):766-772.
  5. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA. Sci Transl Med. 2017 Sep 13;9 (407).
  6. A colorectal cancer classification system that associates cellular phenotype and responses to therapy Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschlegler S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. Nature Medicine. 2013 May;19(5):619-25.
  7. The consensus molecular subtypes of colorectal cancer Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Song S, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Taberero J, Bernardis R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. Nature Medicine. 2015 Nov;21(11):1350-6.